Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.